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Purpose: Animal tumor models are important for the evaluation of novel therapeutic 
modalities. Since the initial report of an orthotopic bladder tumor model, several mod-
ifications have been proposed to improve the tumor take rate. Here we compared the 
HCl-pretreated and electrocauterization-pretreated orthotopic murine bladder tumor 
models.
Materials and Methods: MBT-2 murine bladder cancer cells were transurethrally im-
planted in the bladder of syngeneic C3H/He mice. The mice were divided into three 
groups according to pretreatment methods (electrocautery, HCl, and control group) and 
were subjected to pretreatment before instillation of MBT-2 tumor cells into the 
bladder. Mice were sacrificed on day 21, and bladders were harvested, weighed, and 
examined histopathologically.
Results: The tumor take rate of the control, electrocautery, and HCl groups was 0%, 
54%, and 100%, respectively. The tumor take rate of the HCl group was significantly 
higher than that of the control group (p＜0.01) and the electrocautery group (p=0.01). 
Pathologic reports revealed that all established bladder tumors were high-grade papil-
lary urothelial carcinomas.
Conclusions: The HCl pretreatment model was a preferable murine bladder tumor mod-
el for evaluating further therapeutic interventions.
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The gold standard of treatment for patients with non-mus-
cle-invasive bladder cancer is transurethral resection. 
However, the high rate of recurrence or progression pres-
ents a major problem despite current intravesical chemo-
therapy and immunotherapy treatments. It is necessary to 
evaluate novel intravesical treatment strategies capable 
of providing improved efficacy and lower toxicity.
Animal cancer models are important for the evaluation 
of new treatment modalities [1,2]. A suitable bladder tu-
mor model that resembles human disease is essential for 
evaluation [3]. Orthotopic bladder tumor models simulate 
the local cancer environment and resemble the behavior of 
human disease. An ideal orthotopic model should be easy 
to perform and should allow a high tumor take rate [4].
Soloway [5] described the first transplantable orthotopic 
bladder tumor model. Since this initial report, several mod-
ifications have been proposed to improve the technique and 
increase the success rate of orthotopic bladder tumor im-
plantation to tumor take rates of 30 to 100% [4,6,7]. Here 
we compared the tumor take rate of hydrochloric acid 
(HCl)-pretreated and electrocauterization-pretreated or-
thotopic murine bladder tumor models.
MATERIALS AND METHODS
1. Bladder cancer cell line preparation
The MBT-2 murine bladder cancer cell line was originally 
provided by Dr. Koh (Korea Advanced Institute of Science Korean J Urol 2012;53:396-400
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TABLE 1. Incidence and stage according to experimental group
Group (n)
Histology Tumor take 
rate (%) T 0 C I S T 1T 2T 3T 4
C o n t r o l  ( 5 )5 00000 0
Electrocautery (11) 5 0 6 0 0 0 54
HCl (11) 0 0 9 2 0 0 100
CIS, Carcinoma in situ.
and Technology, Daejeon, Korea). MBT-2 is a poorly differ-
entiated murine bladder cancer cell line derived from a 
transplantable N-[4-(5-nitro-2-furyl)-2-thiazolyl] forma-
mide-induced bladder cancer in a female C3H/He mouse. 
The cells were cultured in Roswell Park Memorial Insti-
tute-1600 medium with 10% fetal bovine serum (KDR 
Biotech Co., Seoul, Korea) and 100 µg/ml streptomycin 
(Chong Kun Dang, Seoul, Korea) in a 5% CO2 atmosphere 
at 37
oC. The culture medium was replaced every other day, 
and subculture was performed when the cellular con-
fluence reached 90%. Cells were harvested from subcon-
fluent cultures by trypsinization and were washed in se-
rum-free medium. Single cell suspensions with ＞90% cell 
viability were determined by Trypan blue exclusion. The 
cells were resuspended in phosphate-buffered saline (PBS; 
KDR Biotech Co.) before injection.
2. Animals
Six-week-old female C3H/He mice were purchased from 
Orient Bio Inc. (Seongnam, Korea) and raised for 2 weeks. 
All animal experimental procedures were approved by the 
Kangbuk Samsung Hospital Animal Care and Use 
Committee.
3. Creation of orthotopic murine bladder cancer models
Animals were divided into three groups: control group, 
electrocautery group, and HCl group. The control group 
had 5 mice, whereas the electrocautery and HCl groups had 
11 mice each. Mice were anesthetized with 0.02 ml/100 g 
intramuscular injection of a 1:2 mixture of tiletamine/zo-
lazepam (Zoletil-50, Virbac, Carros cedex, France) and xy-
lazine HCl (Rompun, Bayer Korea Ltd, Seoul, Korea). 
Intramuscular injection of 20 mg/kg of cefotetan (Yamate-
tan, Jeil Pharmaceutical Co., Seoul, Korea) was repeated 
every 12 hours for 3 days after inoculation.
Control group: After anesthesia, a 24-gauge intravenous 
catheter was inserted into the bladder through the urethra. 
MBT-2 cells (1.2x10
6) in 50 μl of medium were instilled. The 
urethra was then ligated immediately after catheter re-
moval by use of 4-0 silk. The cells were left to dwell within 
the bladder for 1 hour, followed by removal of the urethral 
ligature to allow voiding.
Electrocautery group: After anesthesia, a 24-gauge in-
travenous catheter was inserted into the bladder through 
the urethra. A metal electrode was inserted in the bladder 
through the catheter, and the tip of the electrode contacted 
the bladder mucosa. With the animal on a grounding plate, 
a monopolar electrocautery current was applied for 1 
second. The electrode was removed and 1.2x10
6 MBT-2 
cells were instilled. The urethra was ligated immediately 
to allow the cells to dwell in the bladder for 1 hour before 
voiding, as described for the control mice.
HCl group: After anesthesia, a 24-gauge intravenous 
catheter was inserted into the bladder through the urethra 
and 30 μl of 0.1 N HCl was injected into the bladder through 
the catheter. The acid solution was allowed to remain in the 
bladder for 15 seconds before replacement with 30 μl of 0.1 
N NaOH for 15 seconds. The bladder was then drained and 
flushed with sterile PBS. MBT-2 cells (1.2×10
6) in 50 μl of 
medium were instilled and the urethra was ligated imme-
diately to allow the cells to dwell in the bladder for 1 hour 
before voiding as described for the control mice.
On day 21, all mice were sacrificed by CO2 euthanasia. 
No mice had died due to complications during the ex-
perimental period. Each bladder was harvested, weighed, 
and subjected to histopathological examination. The pres-
ence or absence of tumors was noted, along with the mor-
phology and tumor size and weight. The tumor volume was 
determined by using the formula for a rational ellipse 
(0.5236×l×w×h) [8]. Tissue from bladders was stained with 
hematoxylin-eosin for histologic examination. Statistical 
analyses were carried out by using SPSS ver. 15.0 (SPSS 
Inc., Chicago, IL, USA) for Windows. Differences in tumor 
volume and weight between the two groups were compared 
by using Student’s t-test, and the tumor take rate was com-
pared by using the Pearson chi-square test. A p-value＜ 
0.05 was considered to be statistically significant.
RESULTS
In the control group, a single cell suspension of 1.2×10
6 
MBT-2 cells instilled into the bladder did not result in tu-
mor establishment. In contrast, bladder tumors were es-
tablished in 6 of 11 mice in the electrocautery group and 
11 of 11 mice in the HCl group. The tumor take rate of the 
electrocautery (54%, p=0.03) and HCl (100%, p＜0.01) 
groups were higher than that of the control group (0%). 
Between two experimental groups, the tumor take rate of 
the HCl group was significantly higher than that of electro-
cautery group (p=0.01) (Table 1).
The average tumor volume of the electrocautery and HCl 
groups were 221.55±118.63 mm
3 and 268.52±171.14 mm
3. Korean J Urol 2012;53:396-400
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FIG. 1. Gross images of the bladder in each experimental group. (A) Normal bladder from the control group. (B) Bladder tumor from 
the electrocautery group. (C) Bladder tumor from the HCl group.
FIG. 2. (A) An example from the electrocautery group. The tumor invades into the submucosa but does not involve proper muscle. The 
tumor shows a solid growth pattern with high-grade urothelial carcinoma cells (H&E, ×100). (B) An example from the HCL group. 
The tumor shows a solid infiltrative growth pattern with high-grade urothelial carcinoma cells. The tumor invades into the proper 
muscle. (H&E, ×100).
There was no statistic difference between two groups 
(p=0.35) (Fig. 1).
The average tumor weight of the electrocautery 
(243.2±91.1 mg) and HCl (278.5±179.9 mg) groups also did 
not differ significantly (p=0.40).
The pathologic reports for all the established bladder tu-
mors were high grade papillary urothelial carcinoma, same 
as MBT-2 cell line. In the electrocautery group, all the es-
tablished tumors were limited to the mucosal and sub-
mucosal layer (pT1). In the HCl group, tumors from nine 
mice were limited to the mucosal and submucosal layer 
(pT1), whereas two showed invasion into the muscular lay-
er (pT2) (Table 1) (Fig. 2).
DISCUSSION
Treatment for localized bladder cancer includes transure-
thral tumor resection. Despite intravesical immunothe-
rapy or chemotherapy, up to 70% of patients with super-
ficial bladder cancer develop recurrent tumors. Novel ther-
apeutic agents are needed to improve the outlook of bladder 
cancer treatment.
Animal cancer models are important for evaluating the 
effects of different therapeutic interventions [1,2]. A suit-
able bladder tumor model should resemble human disease 
in both histology and behavior [3]. Thus, the tumor should 
grow intravesically and should consist of pure urothelial 
cancer cells (transitional cells). Furthermore, non-mus-
cle-invasive tumors are preferable, because 70 to 80% of hu-Korean J Urol 2012;53:396-400
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man bladder tumors are non-muscle-invasive. In addition, 
the establishment of the model should be technically easy 
to develop within a reasonable time period.
Currently, there are three fundamental murine bladder 
tumor models: chemically induced bladder cancer [9-12], 
the xenograft model (transplantation of human transi-
tional cell carcinoma (TCC) into immunodeficient mice) 
[13-15], and the syngeneic tumor model (transplantation 
of carcinogen-induced bladder cancer cells into syngeneic, 
immunocompetent mice) [5,16-19]. Chemical induction of 
primary bladder tumors requires several months, with 
both TCC and squamous carcinoma being induced, and tis-
sues other than urothelium also being transformed 
[20-23]. The xenograft model, which uses immunodeficient 
nude mice, is compromised in its ability to develop an ad-
equate immune reaction to an immunological stimulus 
[24]. In the syngeneic tumor model, the heterotopic tumor 
model is not suitable owing to its dissimilarities in bio-
logical behavior compared to the clinical disease [3].
The orthotopic bladder tumor model resembles the hu-
man situation resulting from seeding of viable tumor cells 
to the bladder mucosa. [3,4]. However, the orthotopic tech-
nique cannot guarantee a high tumor take rate in usual 
settings. The bladder mucosa and the GAG layer act as nat-
ural protective layers against external insults, and this 
may result in a poor tumor take rate [4,25]. 
Soloway [5] described the first transplantable orthotopic 
bladder tumor model. With the administration of N-meth-
yl-N-nitrosourea before tumor instillation, they reported 
a tumor take rate of about 60%. However, only extravesi-
cally implanted tumors were obtained with this technique 
[6]. Several modifications have been proposed to improve 
the techniques and the success rate of orthotopic bladder 
tumor implantation. Shapiro et al. [6] reported a tumor 
take rate of about 60% with electrocauterization-induced 
mucosal injury before tumor instillation. In this mod-
ification, extravesical tumors were reduced to 24%. Similar 
results were reported by Sindhwani et al. [26], who de-
scribed a 73% tumor take rate and about 30% extravesical 
tumors with electrocautery pretreatment. Pretreatment 
with HCl/KOH resulted in a tumor take rate of about 80 
to 90%, with about 20% extravesical tumors [27,28].
In the HCl pretreatment model, it may be possible to ex-
pose the entire bladder wall to acid, leading to extensive 
mucosal injury. Chan et al. [4] reported a high mortality 
rate and extensive bladder wall inflammation in the HCl 
pretreatment group. The high mortality rate of this model 
is a serious pitfall, however, and the presence of extensive 
inflammation decreases the similarity of the model to hu-
man disease, because a considerable portion of the human 
bladder wall remains grossly normal during transurethral 
resection. We note that there are some technical differ-
ences between the previously reported HCl pretreatment 
model and the model we reported here. Chan et al. [4] filled 
the bladder with 100 μl of 0.1 N HCl solution, whereas we 
used 30 μl. Also, they did not use antibiotic agents. In our 
experiment, the HCl pretreatment group experienced no 
mortality, and microscopic examination revealed the ab-
sence of inflammation or ulceration in the bladder. Several 
other reports have also described the absence of a high mor-
tality or morbidity rate in HCl pretreatment models [27- 
29]. Thus, the high mortality rate and extensive mucosal 
injury did not seem to be correlated with HCl pretreatment, 
but may rather reflect technical issues that could be cor-
rected with certain procedural modifications and cautions.
In our study, the HCl pretreatment group showed a 100% 
tumor take rate with 18% muscle invasion, which was su-
perior to both the control and the electrocautery pretreat-
ment groups. The tumor take rate was superior to those in 
previous reports, and the low muscle invasion rate was 
comparable to that reported in other studies.
CONCLUSIONS
The orthotopic murine bladder cancer model is ideal for the 
evaluation of novel intravesical therapy. But, on account 
of the low tumor take rate, several modifications have been 
proposed. On the basis of our findings, we suggest that the 
HCl pretreatment model is the preferable murine bladder 
cancer model for evaluating further therapeutic inter-
ventions.
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